Unveiling several transformational changes to reach new guests, Olive Garden announced its first new national advertising campaign in nearly 10 years and the initial phase of significant menu innovations that include lighter Italian entrées, new Porta Vita signature wines and a unique “Dinner Today & Dinner TomorrowSM” limited-time offer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57988-olive-garden-unveils-transformational-changes
Typical bathroom products like shampoo bottles, toilet paper rolls and toothpaste boxes are significantly less likely to be recycled than kitchen products according to survey results released today by the Ad Council. Nonprofits Keep America Beautiful and the Ad Council have joined with Unilever to expand the conversation around recycling and motivate more Americans to remember to recycle in the bathroom by launching a new phase of the national, award-winning “I Want To Be Recycled” communications campaign, featuring a brand new series of broadcast and digital PSAs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7444951-keep-america-beautiful-recycle/
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
The Ad Council, in partnership with the U.S. Department of the Treasury and the U.S. Department of Housing and Urban Development (HUD), have joined together to launch a new phase of their Foreclosure Prevention Assistance Public Service Advertising (PSA) Campaign. The campaign aims to increase awareness of the Making Home Affordable® Program’s free resources and assistance for homeowners who are struggling with their mortgage payments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51783-ad-council-making-home-affordable-english-psa
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
XCMG, the world’s fifth largest construction equipment company, unveils the XE15R hydraulic intelligent excavator, its first fully remote-controlled excavator, signaling a new phase in XCMG’s intelligentization of its excavator series.
Without a cab, XE15R is the company’s smallest excavator at 1.35m in height and 1.08m in width. Nicknamed “Little Swan”, the machine is agile and flexible in challenging working conditions.
The newly developed XE15R features a wireless control function with a 100-meter range, and integrates mechanic, electronic and hydraulic control technology with a CAN bus interface design. Unmanned driving reduces labor intensity, particularly useful in severe operating environments, such as toxic conditions or extreme temperatures.
As an intelligent excavator, XE15R also features a self-learning function. It can save operating maneuvers and then replay them automatically on request, a breakthrough that further ensures security, agility and reliability in operation.
“Intelligentization is an inevitable choice as XCMG follows the path of new industrialization, and XE15R shows that we do what we say. Its design embodies our pursuit of efficiency and user friendliness.” said Wang Min, president of XCMG. The launching of XE15R expands XCMG’s product line, and improves its customers’ construction quality, providing them with a more human-friendly working environment and better project solutions.
To view the multimedia release please visit
http://www.multivu.com/players/English/7605551-xcmg-xe15r-remote-controlled-excavator/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Bacardi Limited, the largest privately held spirits company in the world, today announced the initial phase of its US$250 million dollar investment in Scotch whisky production has been completed. This investment is to meet growing demand for the premium portfolio of Dewar’s Scotch whiskies, which are among the top-selling, favorite and most awarded Scotches in the world.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bacardi/46020/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Today Concentrix Corporation, a wholly-owned subsidiary of SYNNEX Corporation (NYSE: SNX), announced the addition of 19 delivery locations, across 13 countries, completing the second phase of the acquisition of IBM's global customer care and industry process services business. With over 95% of the acquisition completed, Concentrix continues to advance its position as a leader in the customer care and industry process services market, with over 45,000 employees delivering high value services.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7146451-concentrix-completes-2nd-phase-of-ibm-customer-care-business-acquisition
